Interacciones de Bosutinib
Bosutinib (Bosulif) tiene 79 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 65; moderadas: 14; leves: 0; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.
Interacciones según la etiqueta
Interacciones graves (65)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
• Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (etiqueta de Bosutinib, Interacciones medicamentosas)
Interacciones moderadas (14)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Proton Pump Inhibitors (PPI) As an alternative to PPIs, use short-acting antacids or H2 blockers and separate dosing by more than 2 hours from BOSULIF dosing. (etiqueta de Bosutinib, Interacciones medicamentosas)
Compruebe Bosutinib frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.
Abrir en el verificadorNo es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.